Mylan acquired worldwide commercialization rights to Novartis's cystic fibrosis franchise (TOBI Podhaler dry powder inhaler and TOBI inhalation solution) for $463M, with agreement signed July 30 and closing August 31, 2018. ~$240M payable in 2018. Strengthens Mylan's CF and respiratory portfolio with established inhaled tobramycin products.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 31, 2018
ClosedAug 31, 2018
Deal value$463M
Deal typeAsset Purchase
Therapeutic areaLung infections in cystic fibrosis